• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Olfaction before and after initiation of elexacaftor-tezacaftor-ivacaftor in a cystic fibrosis cohort.在一个囊性纤维化队列中，使用依列卡福-替扎卡福-依伐卡福前后的嗅觉情况。
Int Forum Allergy Rhinol. 2022 Feb;12(2):223-226. doi: 10.1002/alr.22891. Epub 2021 Oct 28.
2
Is Elexacaftor/Tezacaftor/Ivacaftor Effective in Treating Sinonasal Disease in Patients with Cystic Fibrosis?依列卡福妥/替扎卡福妥/依伐卡托对治疗囊性纤维化患者的鼻窦疾病有效吗？
Laryngoscope. 2024 Feb;134(2):501-503. doi: 10.1002/lary.30937. Epub 2023 Aug 7.
3
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
4
Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.用于治疗囊性纤维化的依列卡福妥/替扎卡福妥/依伐卡托（三联疗法）
Med Lett Drugs Ther. 2020 Jan 13;62(1589):5-7.
5
Questions and Answers? Depression Symptoms Associated with Elexacaftor/Tezacaftor/Ivacaftor Treatment for Cystic Fibrosis.问答：与依列卡福妥/替扎卡福妥/依伐卡福妥治疗囊性纤维化相关的抑郁症状
Am J Respir Crit Care Med. 2024 Feb 1;209(3):239-241. doi: 10.1164/rccm.202311-2159ED.
6
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
7
Elexacaftor/tezacaftor/ivacaftor in children aged 6-11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: A 24-week observational study.针对年龄在6至11岁、患有囊性纤维化、至少有一个F508DEL等位基因且患有晚期肺部疾病的儿童使用依列卡福妥/替扎卡福妥/依伐卡托：一项为期24周的观察性研究。
Pediatr Pulmonol. 2022 Sep;57(9):2253-2256. doi: 10.1002/ppul.25980. Epub 2022 May 25.
8
Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare variants: a viewpoint.收集真实世界的同情用药数据以扩大艾列卡福托/替扎卡福托/依伐卡托对携带N1303K或其他罕见变异的囊性纤维化患者的适用范围：一种观点
Eur Respir J. 2024 Jan 25;63(1). doi: 10.1183/13993003.01959-2023. Print 2024 Jan.
9
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.依列卡福妥联合替扎卡福妥和依伐卡托对比替扎卡福妥联合依伐卡托治疗F508del-CFTR纯合子囊性纤维化患者的疗效和安全性：一项为期24周的多中心、随机、双盲、活性对照3b期试验
Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20.
10
Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.支持对无F508del CFTR变异的囊性纤维化患者采用依列卡福/替扎卡福/依伐卡福靶向治疗方案的理由：法国同情用药计划的进一步分析
Eur Respir J. 2024 Feb 29;63(2). doi: 10.1183/13993003.01392-2023. Print 2024 Feb.

引用本文的文献

1
A 3-Week Inpatient Rehabilitation Programme Improves Body Composition in People with Cystic Fibrosis with and Without Elexacaftor/Tezacaftor/Ivacaftor Therapy.一项为期3周的住院康复计划可改善接受或未接受依列卡福/替扎卡福/依伐卡福治疗的囊性纤维化患者的身体组成。
Nutrients. 2025 Jul 25;17(15):2439. doi: 10.3390/nu17152439.
2
Exploration of Olfaction and ChiPSO in Pediatric Cystic Fibrosis.小儿囊性纤维化中嗅觉与ChiPSO的探索
J Clin Med. 2025 Apr 9;14(8):2583. doi: 10.3390/jcm14082583.
3
Elexacaftor-Tezacaftor-Ivacaftor Improves Sinonasal Outcomes in Young Children With Cystic Fibrosis.依列卡福妥-替扎卡福妥-依伐卡福妥改善了患有囊性纤维化的幼儿的鼻窦结局。
Int Forum Allergy Rhinol. 2025 Jul;15(7):706-714. doi: 10.1002/alr.23555. Epub 2025 Mar 2.
4
The impact of highly effective modulator therapy on sinusitis and dysosmia in young children with cystic fibrosis: a prospective study protocol.高效调节剂疗法对囊性纤维化幼儿鼻窦炎和嗅觉障碍的影响：一项前瞻性研究方案
ERJ Open Res. 2025 Jan 13;11(1). doi: 10.1183/23120541.00137-2024. eCollection 2025 Jan.
5
Olfactory loss in people with cystic fibrosis: Community perceptions and impact.囊性纤维化患者的嗅觉丧失：社区认知与影响。
J Cyst Fibros. 2024 Nov;23(6):1195-1198. doi: 10.1016/j.jcf.2023.11.006. Epub 2023 Nov 18.
6
Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis.依列卡福妥-替扎卡福妥-依伐卡托：用于囊性纤维化的改变人生的三联组合CFTR调节剂药物。
Pharmaceuticals (Basel). 2023 Mar 8;16(3):410. doi: 10.3390/ph16030410.
7
Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis.依伐卡托与泰他卡托和艾美卡替联合治疗可改善囊性纤维化患者的鼻窦结局。
J Cyst Fibros. 2022 Sep;21(5):792-799. doi: 10.1016/j.jcf.2022.03.002. Epub 2022 Mar 14.

本文引用的文献

1
Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis.高效调节剂治疗对囊性纤维化成人生活质量的影响。
Int Forum Allergy Rhinol. 2021 Jan;11(1):75-78. doi: 10.1002/alr.22700. Epub 2020 Sep 28.
2
Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.囊性纤维化跨膜电导调节剂调节剂治疗：耳鼻喉科医生的综述。
Am J Rhinol Allergy. 2020 Jul;34(4):573-580. doi: 10.1177/1945892420912368. Epub 2020 Mar 13.
3
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.VX-445-泰泽卡托维瓦卡托联合治疗伴有一个或两个 Phe508del 等位基因的囊性纤维化患者。
N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.
4
Smell in cystic fibrosis.囊性纤维化中的嗅觉
Eur Arch Otorhinolaryngol. 2013 Mar;270(3):915-21. doi: 10.1007/s00405-012-2124-2. Epub 2012 Aug 14.
5
Chemosensory function and food preferences of children with cystic fibrosis.囊性纤维化患儿的化学感觉功能和食物偏好。
Pediatr Pulmonol. 2010 Aug;45(8):807-15. doi: 10.1002/ppul.21261.
6
The influence of olfactory loss on dietary behaviors.嗅觉丧失对饮食行为的影响。
Laryngoscope. 2008 Jan;118(1):135-44. doi: 10.1097/MLG.0b013e318155a4b9.
7
Olfactory epithelia exhibit progressive functional and morphological defects in CF mice.在囊性纤维化（CF）小鼠中，嗅觉上皮表现出渐进性的功能和形态缺陷。
Am J Physiol Cell Physiol. 2007 Aug;293(2):C574-83. doi: 10.1152/ajpcell.00106.2007. Epub 2007 Apr 11.
8
Olfactory dysfunction in patients with head trauma.头部创伤患者的嗅觉功能障碍。
Arch Neurol. 1997 Sep;54(9):1131-40. doi: 10.1001/archneur.1997.00550210061014.
9
Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function.宾夕法尼亚大学嗅觉识别测试的开发：一种标准化的嗅觉功能微胶囊测试。
Physiol Behav. 1984 Mar;32(3):489-502. doi: 10.1016/0031-9384(84)90269-5.

Olfaction before and after initiation of elexacaftor-tezacaftor-ivacaftor in a cystic fibrosis cohort.

作者信息

Bacon Daniel R, Stapleton Amanda, Goralski Jennifer L, Ebert Charles S, Thorp Brian D, Nouraie Mehdi, Shaffer Amber D, Senior Brent A, Lee Stella E, Zemke Anna C, Kimple Adam J

机构信息

Department of Otolaryngology - Head & Neck Surgery, University of North Carolina, North Carolina, USA.

Department of Otolaryngology, University of Pittsburgh, Pittsburgh, USA.

出版信息

Int Forum Allergy Rhinol. 2022 Feb;12(2):223-226. doi: 10.1002/alr.22891. Epub 2021 Oct 28.

DOI:10.1002/alr.22891
PMID:34709729
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8792160/
Abstract
摘要